Antiepileptic effects of levetiracetam in a rodent neonatal seizure model

Pediatric Research

Volumn 73, Issue 1, 2013, Pages 24-30

  Talos, Delia M ^a,d   Chang, Meayoung ^a,e   Kosaras, Bela ^a   Fitzgerald, Erin ^a   Murphy, Andrew ^a,b   Folkerth, Rebecca Dunn ^a,b   Jensen, Frances E ^a,c,f  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Chungnam National University   (South Korea)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; ETIRACETAM; KAINIC ACID; SYNAPTIC VESICLE PROTEIN 2A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFICACY; ELECTROGRAPHY; INFANTILE SPASM; MALE; NEWBORN HYPOXIA; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; ANTICONVULSANTS; BLOTTING, WESTERN; BRAIN; IMMUNOHISTOCHEMISTRY; KAINIC ACID; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; PIRACETAM; RATS; SEIZURES;

EID: 84872072625     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2012.151     Document Type: Article

References (40)

1. Silverstein FS, Jensen FE. Neonatal seizures. Ann Neurol 2007;62:112-20.
2. Sankar R, Painter MJ. Neonatal seizures: after all these years we still love what doesn't work. Neurology 2005;64:776-7.
3. Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66:1654-60.
4. Khurana DS, Kothare SV, Valencia I, Melvin JJ, Legido A. Levetiracetam monotherapy in children with epilepsy. Pediatr Neurol 2007;36:227-30.
5. Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broadspectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008;54:715-20.
6. Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci 1994;14:5223-35.
7. Yang XF, Rothman SM. Levetiracetam has a time-and stimulationdependent effect on synaptic transmission. Seizure 2009;18:615-9.
8. Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003;45:661-71.
9. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002;43:9-18.
10. Lcher W, Hack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284:474-9.
11. Stratton SC, Large CH, Cox B, Davies G, Hagan RM. Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res 2003;53:95-106.
12. Yan HD, Ji-qun C, Ishihara K, Nagayama T, Serikawa T, Sasa M. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia 2005;46:1170-7.
13. Vinogradova LV, van Rijn CM. Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. Epilepsia 2008;49:1160-8.
14. Lamberty Y, Margineanu DG, Klitgaard H. Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdalakindled rats. Epilepsy Behav 2000;1:333-42.
15. Khan O, Chang E, Cipriani C, Wright C, Crisp E, Kirmani B. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol 2011;44:265-9.
16. Abend NS, Gutierrez-Colina AM, Monk HM, Dlugos DJ, Clancy RR. Levetiracetam for treatment of neonatal seizures. J Child Neurol 2011;26:465-70.
17. Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol 2011;15:1-7.
18. Fwentsches A, Bussmann C, Ramantani G, et al. Levetiracetam in the treatment of neonatal seizures: a pilot study. Seizure 2010;19:185-9.
19. Kim JS, Kondratyev A, Tomita Y, Gale K. Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. Epilepsia 2007;48:Suppl 5:19-26.
20. Manthey D, Asimiadou S, Stefovska V, et al. Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp Neurol 2005;193:497-503.
21. Koh S, Jensen FE. Topiramate blocks perinatal hypoxia-induced seizures in rat pups. Ann Neurol 2001;50:366-72.
22. Koh S, Tibayan FD, Simpson JN, Jensen FE. NBQX or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury. Epilepsia 2004;45:569-75.
23. Jensen FE, Applegate CD, Holtzman D, Belin TR, Burchfiel JL. Epileptogenic effect of hypoxia in the immature rodent brain. Ann Neurol 1991;29:629-37.
24. Rakhade SN, Klein PM, Huynh T, et al. Development of later life spontaneous seizures in a rodent model of hypoxia-induced neonatal seizures. Epilepsia 2011;52:753-65.
25. Jensen FE, Holmes GL, Lombroso CT, Blume HK, Firkusny IR. Age-dependent changes in long-term seizure susceptibility and behavior after hypoxia in rats. Epilepsia 1992;33:971-80.
26. Aujla PK, Fetell MR, Jensen FE. Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model. Epilepsia 2009;50:694-701.
27. Jensen FE, Blume H, Alvarado S, Firkusny I, Geary C. NBQX blocks acute and late epileptogenic effects of perinatal hypoxia. Epilepsia 1995;36: 966-72.
28. Jensen FE, Wang C. Hypoxia-induced hyperexcitability in vivo and in vitro in the immature hippocampus. Epilepsy Res 1996;26:131-40.
29. Rakhade SN, Zhou C, Aujla PK, Fishman R, Sucher NJ, Jensen FE. Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures. J Neurosci 2008;28:7979-90.
30. Mikati MA, Zeinieh MP, Kurdi RM, et al. Long-term effects of acute and of chronic hypoxia on behavior and on hippocampal histology in the developing brain. Brain Res Dev Brain Res 2005;157:98-102.
31. Talos DM, Sun H, Zhou X, et al. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS ONE 2012;7:e35885.
32. Zhou C, Lippman JJ, Sun H, Jensen FE. Hypoxia-induced neonatal seizures diminish silent synapses and long-term potentiation in hippocampal CA1 neurons. J Neurosci 2011;31:18211-22.
33. Sanchez RM, Dai W, Levada RE, Lippman JJ, Jensen FE. AMPA/kainate receptor-mediated downregulation of GABAergic synaptic transmission by calcineurin after seizures in the developing rat brain. J Neurosci 2005;25:3442-51.
34. Merhar SL, Schibler KR, Sherwin CM, et al. Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr 2011;159:152-154. e3.
35. van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia 2009;50: 422-33.
36. Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci 2003;993:103-14; discussion 123-4.
37. Grosso S, Cordelli DM, Franzoni E, et al. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. Seizure 2007;16:345-50.
38. Quilichini PP, Diabira D, Chiron C, Milh M, Ben-Ari Y, Gozlan H. Effects of antiepileptic drugs on refractory seizures in the intact immature corticohippocampal formation in vitro. Epilepsia 2003;44:1365-74.
39. Glantz LA, Gilmore JH, Hamer RM, Lieberman JA, Jarskog LF. Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood. Neuroscience 2007;149:582-91.
40. Toering ST, Boer K, de Groot M, et al. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers. Epilepsia 2009;50:1409-18.